MedTrace Logo

Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis

NCT04002349 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-06-28

No results posted yet for this study

Summary

Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe economic and social burden, as well as the potential risk of developing other chronic diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to explore the classification and treatment strategies of chronic rhinitis in order to improve the health level of Chinese people.

Conditions

  • Determination of the Efficacy of Different Medications for Idiopathic Rhinitis
  • Impact of Different Medications on Biomarkers of Idiopathic Rhinitis
  • Safety and Tolerance of Different Medications for Idiopathic Rhinitis

Interventions

DRUG

Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)

Detailed in arm descriptions

DRUG

Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)

Detailed in arm descriptions

DRUG

0.9% natural saline

Detailed in arm descriptions

Sponsors & Collaborators

  • Beijing Institute of Otolaryngology

    collaborator UNKNOWN

  • Shanghai Johnson & Johnson Pharmaceuticals, Ltd.

    collaborator UNKNOWN

  • Beijing Tongren Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2019-12-31
Completion
2020-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04002349 on ClinicalTrials.gov